GP1BA and Thrombocytopenia: Our results support the work of Boilard et al.[25], who noted that a polyclonal anti-platelet treatment (anti-GPIbα) reduced inflammation up to 85% relative to arthritic controls, while causing thrombocytopenia up to 6 days from induction [32].